Chong Kun Dang Holdings Corp. (001630.KS)
KRW 46150.0
(-0.43%)
KRW 46150.0
(-0.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 422.84 Billion KRW | 7.48% |
| 2022 | 393.4 Billion KRW | 48.19% |
| 2021 | 265.47 Billion KRW | 45.7% |
| 2020 | 182.2 Billion KRW | 60.16% |
| 2019 | 113.76 Billion KRW | 224.98% |
| 2018 | 35 Billion KRW | 550.96% |
| 2017 | -7.76 Billion KRW | 56.16% |
| 2016 | -17.7 Billion KRW | 37.13% |
| 2015 | -28.16 Billion KRW | -292.1% |
| 2014 | 14.65 Billion KRW | 344.04% |
| 2013 | -6 Billion KRW | -104.17% |
| 2012 | 144.13 Billion KRW | 19.43% |
| 2011 | 120.68 Billion KRW | 26.13% |
| 2010 | 95.68 Billion KRW | -2.46% |
| 2009 | 98.1 Billion KRW | -22.01% |
| 2008 | 125.79 Billion KRW | -3.17% |
| 2007 | 129.9 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 421.96 Billion KRW | 3.87% |
| 2024 Q1 | 406.23 Billion KRW | -3.93% |
| 2023 FY | 422.84 Billion KRW | 7.48% |
| 2023 Q2 | 402.78 Billion KRW | 0.91% |
| 2023 Q1 | 399.14 Billion KRW | 1.46% |
| 2023 Q4 | 422.84 Billion KRW | -2.24% |
| 2023 Q3 | 432.54 Billion KRW | 7.39% |
| 2022 Q1 | 268.97 Billion KRW | 1.32% |
| 2022 Q2 | 318.04 Billion KRW | 18.24% |
| 2022 Q4 | 393.4 Billion KRW | 11.44% |
| 2022 Q3 | 353.01 Billion KRW | 10.99% |
| 2022 FY | 393.4 Billion KRW | 48.19% |
| 2021 Q4 | 265.47 Billion KRW | 13.0% |
| 2021 Q3 | 234.92 Billion KRW | 11.8% |
| 2021 Q2 | 210.12 Billion KRW | 22.86% |
| 2021 Q1 | 171.02 Billion KRW | -6.14% |
| 2021 FY | 265.47 Billion KRW | 45.7% |
| 2020 Q1 | 135.83 Billion KRW | 19.4% |
| 2020 Q2 | 169.63 Billion KRW | 24.88% |
| 2020 FY | 182.2 Billion KRW | 60.16% |
| 2020 Q3 | 169.44 Billion KRW | -0.11% |
| 2020 Q4 | 182.2 Billion KRW | 7.53% |
| 2019 Q2 | 56.33 Billion KRW | 9.3% |
| 2019 FY | 113.76 Billion KRW | 224.98% |
| 2019 Q4 | 113.76 Billion KRW | 7.07% |
| 2019 Q1 | 51.53 Billion KRW | 47.23% |
| 2019 Q3 | 106.25 Billion KRW | 88.62% |
| 2018 FY | 35 Billion KRW | 550.96% |
| 2018 Q1 | -23.51 Billion KRW | -202.98% |
| 2018 Q2 | 5.59 Billion KRW | 123.78% |
| 2018 Q3 | 13.41 Billion KRW | 139.77% |
| 2018 Q4 | 35 Billion KRW | 161.0% |
| 2017 FY | -7.76 Billion KRW | 56.16% |
| 2017 Q4 | -7.76 Billion KRW | -247.9% |
| 2017 Q3 | 5.24 Billion KRW | -66.64% |
| 2017 Q2 | 15.73 Billion KRW | 60.39% |
| 2017 Q1 | 9.81 Billion KRW | 155.41% |
| 2016 FY | -17.7 Billion KRW | 37.13% |
| 2016 Q4 | -17.7 Billion KRW | -15.73% |
| 2016 Q2 | -10.97 Billion KRW | 57.16% |
| 2016 Q1 | -25.62 Billion KRW | 9.0% |
| 2016 Q3 | -15.29 Billion KRW | -39.36% |
| 2015 FY | -28.16 Billion KRW | -292.1% |
| 2015 Q4 | -28.16 Billion KRW | 41.23% |
| 2015 Q3 | -47.91 Billion KRW | 39.51% |
| 2015 Q2 | -79.21 Billion KRW | -781.21% |
| 2015 Q1 | 11.62 Billion KRW | -20.67% |
| 2014 Q4 | 14.65 Billion KRW | 83.23% |
| 2014 FY | 14.65 Billion KRW | 344.04% |
| 2014 Q3 | 8 Billion KRW | 17.89% |
| 2014 Q2 | 6.78 Billion KRW | 156.0% |
| 2014 Q1 | -12.11 Billion KRW | -101.74% |
| 2013 Q2 | 132.88 Billion KRW | -2.2% |
| 2013 Q3 | 115.86 Billion KRW | -12.8% |
| 2013 Q4 | -6 Billion KRW | -105.18% |
| 2013 FY | -6 Billion KRW | -104.17% |
| 2013 Q1 | 135.87 Billion KRW | -5.73% |
| 2012 FY | 144.13 Billion KRW | 19.43% |
| 2012 Q4 | 144.13 Billion KRW | 0.0% |
| 2012 Q1 | 53.6 Billion KRW | 0.0% |
| 2011 Q1 | 60.96 Billion KRW | 0.0% |
| 2011 Q3 | 79.65 Billion KRW | -9.92% |
| 2011 FY | 120.68 Billion KRW | 26.13% |
| 2011 Q2 | 88.42 Billion KRW | 45.05% |
| 2010 Q2 | 78.99 Billion KRW | -9.89% |
| 2010 Q1 | 87.65 Billion KRW | 0.0% |
| 2010 FY | 95.68 Billion KRW | -2.46% |
| 2010 Q3 | 75.03 Billion KRW | -5.01% |
| 2009 Q1 | 80.86 Billion KRW | 0.0% |
| 2009 FY | 98.1 Billion KRW | -22.01% |
| 2009 Q3 | 74.61 Billion KRW | -8.8% |
| 2009 Q2 | 81.81 Billion KRW | 1.18% |
| 2008 Q1 | 80.24 Billion KRW | 0.0% |
| 2008 Q2 | 67.64 Billion KRW | -15.71% |
| 2008 Q3 | 67.99 Billion KRW | 0.52% |
| 2008 FY | 125.79 Billion KRW | -3.17% |
| 2007 Q3 | 86.13 Billion KRW | -12.27% |
| 2007 FY | 129.9 Billion KRW | 0.0% |
| 2007 Q1 | 101.15 Billion KRW | 0.0% |
| 2007 Q2 | 98.18 Billion KRW | -2.94% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 1857.319% |
| Yuhan Corporation | -69.18 Billion KRW | 711.161% |
| Yuhan Corporation | -69.18 Billion KRW | 711.161% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -4703.781% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -4703.781% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -4703.781% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | -36.018% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | -141.661% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 26.08% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -173.912% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -173.912% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | -173.912% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 11572.117% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -1047.859% |
| HANDOK Inc. | 283.45 Billion KRW | -49.174% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -210.932% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -2006.602% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 688.586% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | -147.357% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 364.528% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -264.308% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -608.582% |
| Boryung Corporation | 187.72 Billion KRW | -125.241% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -1738.324% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -263.776% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -458.761% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -458.761% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 1.47% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | -167.119% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 1403.78% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 1045.232% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -412.409% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -17883.142% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -17883.142% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -2474.358% |
| CKD Bio Corp. | 143.29 Billion KRW | -195.082% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | -18.053% |
| JW Holdings Corporation | 480.68 Billion KRW | 12.034% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | -110.425% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 18.352% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | -118.015% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -359668.383% |
| JW Lifescience Corporation | 26.09 Billion KRW | -1520.658% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | -156.917% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -713.553% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -1584.062% |